Results 101 to 110 of about 35,499 (199)

CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV): EFFICACY OF DIFFERENT ANTIEMETIC REGIMENS ACROSS EMETOGENIC RISK LEVELS

Journal of Gandhara Medical and Dental Sciences
OBJECTIVES This audit aimed to determine the efficacy of different antiemetic regimens across emetogenic risk levels in managing chemotherapy-induced vomiting and nausea.
Muhammad Umer Khayyam Azam, Bushra Haider, Nadia Qazi   +2 more
doaj   +1 more source

CLDN18.2 in pancreatic ductal adenocarcinoma: Biomarker assessment, spatial heterogeneity and therapeutic modality selection

Clinical and Translational Discovery, Volume 6, Issue 5, October 2026.
This review presents a framework for selecting Claudin 18.2 (CLDN18.2)‐directed treatment modalities in pancreatic ductal adenocarcinoma according to tumour antigen coverage and spatial distribution. Representative assessment at baseline and reassessment after progression can guide treatment adaptation over time.
Ruyu Tan, Zhexin Zhang, Jiaxin Wang, Roland Andersson, Daniel Ansari, Jinfei Chen   +5 more
wiley   +1 more source

Understanding the Symptom Burden of Complex Skull Base Tumors From the Patient's Perspective

Head &Neck, Volume 48, Issue 10, Page 2720-2732, October 2026.
ABSTRACT Background Symptom burden of skull base tumor (SBT) patients, especially those undergoing multimodality treatment, is poorly understood. We aim to understand symptom burden in this patient group using the core module the MD Anderson Symptom Inventory (MDASI).
Shirley Y. Su, Matheus Sewastjanow‐Silva, Jack Phan, Marc‐Elie Nader, Shaan M. Raza, Franco DeMonte, Paul W. Gidley, Ehab Y. Hanna, Loretta A. Williams   +8 more
wiley   +1 more source

Palonosetron for the prevention of chemotherapy-induced nausea and vomiting: approval and efficacy

, 2009
Rudolph M NavariIndiana University School of Medicine South Bend, South Bend, IN USAAbstract: Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant deterioration in quality of life.
Rudolph M Navari
core  

Olanzapine in Chemotherapy Induced Nausea and Vomiting

, 2021
: Objective: Patients diagnosed with cancer and undergoing chemotherapeutic regimen often anticipate many negative effects of the therapy. Chemotherapy induced nausea and vomiting is of their principal concerns which remains one of the most unpleasant ...
Hussain, Syed Saad, Iqbal, Sarmad, Rahman, Fasiha Abdul   +2 more
core  

Supplemental prophylactic intervention for chemotherapy-induced nausea and emesis (SPICE) trial: Protocol for a multicentre double-blind placebo-controlled randomised trial

, 2020
AIM: There is significant recent interest in the role of ginger root (Zingiber officinale) as an adjuvant therapy for chemotherapy-induced nausea. The supplemental prophylactic intervention for chemotherapy-induced nausea and emesis (SPICE) trial aims to
Marshall, S, Lohning, Anna, Ried, K, Wolfgang Marx, Anna Lohning, Marx, W., Crichton, Megan, Marshall, S., Crichton, M., Elizabeth Isenring, Isenring, E., Karin Ried, Ried, K., Bird, Robert, Molassiotis, A, Skye Marshall, Bird, R, McCarthy, A., McCarthy, Alexandra L., Lohning, A, Molasiotis, A., Ried, Karin, McCarthy, Alexandra, Isenring, E, Robert Bird, Marx, W, Alexandra McCarthy, Alex Molassiotis, Marshall, Skye, Molassiotis, Alex, Megan Crichton, McCarthy, A, Bird, R., Lohning, A., Marx, Wolfgang, Isenring, Elizabeth, Crichton, M   +36 more
core   +1 more source

One cycle of nelarabine given after induction is well tolerated but does not improve outcome in adults with T‐cell precursor acute lymphoblastic leukemia: Outcome data from the UKALL14 randomized‐controlled trial

HemaSphere, Volume 10, Issue 10, October 2026.
Abstract UKALL14 (NCT01085617) T‐cell arm was a phase 3, randomized‐controlled trial. Adults aged 25–65 years were randomized 1:1 at entry to receive standard of care (SOC) or SOC + nelarabine 1.5 g/m2 (Days 1, 3, and 5) to be administered following second induction. The primary end‐point was event‐free survival (EFS).
Clare J. Rowntree, Amy A. Kirkwood, Nadine Farah, Emma Lawrie, David I. Marks, Andrew K. McMillan, Tobias F. Menne, Anthony V. Moorman, Bela Patel, Pip Patrick, Paul Smith, Krisztina Z. Alapi, Lingyi Wang, Marc R. Mansour, Adele K. Fielding   +14 more
wiley   +1 more source

Fatores de risco para náuseas e vômitos pós-operatórios no Hospital Universitário Polydoro Ernanni de São Thiago [PDF]

, 2012
Trabalho de Conclusão de Curso - Universidade Federal de Santa Catarina. Curso de Medicina.
Santos, Michele Caroline
core  

Hematologic Toxicities and Determinants Among Patients With Breast Cancer Treated With Doxorubicin–Cyclophosphamide Followed by Paclitaxel in Northwest Ethiopia: A Retrospective Cohort Study

Health Science Reports, Volume 9, Issue 10, October 2026.
ABSTRACT Background and Aim Hematologic toxicities are common during breast cancer chemotherapy, but data from Ethiopia are limited. This study assessed hematologic toxicities and associated factors among patients treated with doxorubicin‐cyclophosphamide followed by paclitaxel (ACT) regimen in Northwest Ethiopia.
Tegenu Chanie Tesfaye, Rahel Belete Abebe, Gashaw Binega Mekonnen, Ephrem Tafesse Teferi, Mekonnen Melkie Bizuneh, Ashenafi Kibret Sendekie, Tigabu Eskeziya Zerihun, Desalegn Addis Mussie, Abel Temeche Kassaw, Samuel Agegnew Wondm   +9 more
wiley   +1 more source

Management of acute and delayed chemotherapy-induced nausea and vomiting: role of netupitant–palonosetron combination

, 2016
Piotr K JanickiDepartment of Anesthesiology and Perioperative Medicine, Milton S Hershey Medical Center, Pennsylvania State University College of Medicine, Hershey, PA, USAPurpose: The purpose of this review is to summarize and discuss the recently ...
Janicki PK
core